[go: up one dir, main page]

MX2022001510A - Nepicastat para usarse en el tratamiento de dependencia. - Google Patents

Nepicastat para usarse en el tratamiento de dependencia.

Info

Publication number
MX2022001510A
MX2022001510A MX2022001510A MX2022001510A MX2022001510A MX 2022001510 A MX2022001510 A MX 2022001510A MX 2022001510 A MX2022001510 A MX 2022001510A MX 2022001510 A MX2022001510 A MX 2022001510A MX 2022001510 A MX2022001510 A MX 2022001510A
Authority
MX
Mexico
Prior art keywords
nepicastat
dependency
treatment
substance
treating
Prior art date
Application number
MX2022001510A
Other languages
English (en)
Inventor
Tom Woiwode
Mark Moran
Lesley Pickford
Original Assignee
Biotie Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Inc filed Critical Biotie Therapies Inc
Publication of MX2022001510A publication Critical patent/MX2022001510A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan métodos para tratar pacientes que sufren de, o son susceptibles a, al menos un síntoma de abuso, dependencia o abstinencia de al menos una sustancia con el Compuesto A. También se proporcionan métodos para tratar en pacientes al menos una fase de dependencia de al menos una sustancia y métodos para tratar en pacientes al menos una fase de dependencia de cocaína.
MX2022001510A 2007-08-06 2010-02-04 Nepicastat para usarse en el tratamiento de dependencia. MX2022001510A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93532307P 2007-08-06 2007-08-06
US95655507P 2007-08-17 2007-08-17
US96059107P 2007-10-04 2007-10-04

Publications (1)

Publication Number Publication Date
MX2022001510A true MX2022001510A (es) 2022-08-11

Family

ID=40341713

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2015009454A MX357542B (es) 2007-08-06 2008-08-06 Nepicastat para usarse en el tratamiento de dependencia.
MX2018008628A MX391921B (es) 2007-08-06 2008-08-06 Nepicastat para usarse en el tratamiento de dependencia
MX2010001390A MX2010001390A (es) 2007-08-06 2008-08-06 Métodos para el tratamiento de dependencia.
MX2022001510A MX2022001510A (es) 2007-08-06 2010-02-04 Nepicastat para usarse en el tratamiento de dependencia.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2015009454A MX357542B (es) 2007-08-06 2008-08-06 Nepicastat para usarse en el tratamiento de dependencia.
MX2018008628A MX391921B (es) 2007-08-06 2008-08-06 Nepicastat para usarse en el tratamiento de dependencia
MX2010001390A MX2010001390A (es) 2007-08-06 2008-08-06 Métodos para el tratamiento de dependencia.

Country Status (16)

Country Link
US (3) US20090041800A1 (es)
EP (2) EP2182804B1 (es)
JP (5) JP2010535801A (es)
CN (2) CN101815438A (es)
AU (1) AU2008283903B2 (es)
BR (1) BRPI0815089A2 (es)
CA (1) CA2695372C (es)
CO (1) CO6260015A2 (es)
ES (1) ES2638190T3 (es)
IL (1) IL257418A (es)
MX (4) MX357542B (es)
NZ (1) NZ583192A (es)
PH (1) PH12015502210A1 (es)
RU (1) RU2491067C2 (es)
SG (2) SG183696A1 (es)
WO (1) WO2009021055A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008283903B2 (en) * 2007-08-06 2014-01-16 Biotie Therapies, Inc Methods for treating dependence
WO2010124089A2 (en) * 2009-04-22 2010-10-28 Synosia Therapeutics, Inc. Methods for treating dependence
US9804149B2 (en) * 2012-10-10 2017-10-31 Bio-Rad Laboratories, Inc. Patient-based results display
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US20170235908A1 (en) * 2015-11-15 2017-08-17 Oriah Behaviorial Health, Inc. Systems and Methods for Managing and Treating Substance Abuse Addiction
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
AU2018319592B2 (en) 2017-08-20 2024-06-27 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN108066355A (zh) * 2017-12-28 2018-05-25 宁夏恩多芬科技有限公司 Nitrous Oxide作为治疗神经官能症的用途
FR3093419B1 (fr) * 2019-03-08 2021-06-18 Univ Grenoble Alpes Composition et procédé associé de mesure de l’observance thérapeutique
AU2020258086A1 (en) 2019-04-17 2021-11-11 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
AU2020381103B2 (en) * 2019-11-07 2022-08-11 Cybin Uk Ltd Compounds
US11806320B2 (en) * 2020-02-19 2023-11-07 Endo Ventures Limited Isoproterenol compositions and methods
AU2021276656A1 (en) 2020-05-19 2022-11-24 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
AU2021328259A1 (en) * 2020-08-17 2023-02-23 The Research Foundation For Mental Hygiene, Inc. Use of neuromelanin-sensitive MRI as a biomarker of dopamine function
CA3196226A1 (en) * 2020-10-24 2022-04-28 Matthias Emanuel LIECHTI Method of quantifying lysergic acid diethylamide (lsd) and 2,3-dihydro-3-hydroxy-2-oxo lysergide (o-h-lsd) in human plasma
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN112690771B (zh) * 2020-12-09 2022-05-24 华南理工大学 一种利用线性回归模型的人脸视频心率检测方法
CN117098496A (zh) 2021-03-11 2023-11-21 人类生物科学股份有限公司 用于协调包括生物标志物的成像数据集的系统、装置和方法
CN113017632B (zh) * 2021-03-17 2022-11-11 陈思 一种智慧校园心理咨询辅助方法及系统
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
CN119487007A (zh) 2022-09-16 2025-02-18 江苏亚虹医药科技股份有限公司 内匹司他酸加成盐的多晶型及其制备方法和用途
WO2024178082A2 (en) * 2023-02-22 2024-08-29 Freedom Biosciences, Inc. Composition of opioid receptor modulator and mdma for use thereof
CN120754106B (zh) * 2025-09-02 2025-12-09 合肥工业大学 化合物sch23390在制备治疗铅中毒药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE91891T1 (de) * 1987-10-07 1993-08-15 Matrix Technologies Inc Pharmazeutische zusammensetzung fuer die behandlung der kokainsucht.
US5593367A (en) * 1995-08-18 1997-01-14 Deere & Company Switchable ignition and starter control system
EP0883609A1 (en) * 1996-02-23 1998-12-16 Pharmeco Laboratories, Inc. Selective d1 dopamine receptor agonists and partial agonists/antagonists
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
IL156798A0 (en) * 2001-01-17 2004-02-08 Hythiam Inc Use of flumazenil in developing a drug for the treatment of alcohol dependency
US20030040015A1 (en) * 2001-03-07 2003-02-27 Kwang-Soo Kim Methods and reagents for identifying compounds and mutations that modulate dopamine beta-hydroxylase activity
SE0104388D0 (sv) * 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof
US20060058336A1 (en) * 2003-02-27 2006-03-16 Shigetada Nakanishi Pharmaceutical composition for treatment of drug dependence
RU2252756C1 (ru) * 2003-12-23 2005-05-27 Хохлов Александр Петрович Препарат против алкоголизма и наркомании, способ получения такого препарата
AU2008229203B2 (en) * 2007-03-16 2014-05-29 Emory University Methods and compositions for treatment of drug addiction
NZ583193A (en) * 2007-07-23 2012-05-25 Biotie Therapies Inc Treatment of post-traumatic stress disorder with nepicastat
US20090082341A1 (en) * 2007-07-23 2009-03-26 Synosia Therapeutics 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder
AU2008283903B2 (en) 2007-08-06 2014-01-16 Biotie Therapies, Inc Methods for treating dependence
WO2009069669A1 (ja) 2007-11-26 2009-06-04 Bridgestone Corporation 銅－亜鉛合金電気めっき浴およびこれを用いためっき方法

Also Published As

Publication number Publication date
EP3251670A1 (en) 2017-12-06
EP2182804A4 (en) 2010-12-22
WO2009021055A1 (en) 2009-02-12
IL257418A (en) 2018-04-30
NZ583192A (en) 2012-06-29
AU2008283903B2 (en) 2014-01-16
CA2695372A1 (en) 2009-02-12
PH12015502210A1 (en) 2017-04-10
JP2020114883A (ja) 2020-07-30
US10561638B2 (en) 2020-02-18
US20090041800A1 (en) 2009-02-12
MX391921B (es) 2025-03-21
ES2638190T3 (es) 2017-10-19
JP2014148551A (ja) 2014-08-21
BRPI0815089A2 (pt) 2014-09-30
RU2491067C2 (ru) 2013-08-27
SG10201705968RA (en) 2017-08-30
AU2008283903A1 (en) 2009-02-12
SG183696A1 (en) 2012-09-27
JP2016210798A (ja) 2016-12-15
CA2695372C (en) 2013-01-22
US20200383951A1 (en) 2020-12-10
CN106983747A (zh) 2017-07-28
EP2182804B1 (en) 2017-05-24
CN101815438A (zh) 2010-08-25
CO6260015A2 (es) 2011-03-22
US20140099336A1 (en) 2014-04-10
MX2010001390A (es) 2010-08-02
JP2018154645A (ja) 2018-10-04
EP2182804A1 (en) 2010-05-12
JP2010535801A (ja) 2010-11-25
RU2010108249A (ru) 2011-09-20
MX357542B (es) 2018-07-13

Similar Documents

Publication Publication Date Title
MX2022001510A (es) Nepicastat para usarse en el tratamiento de dependencia.
WO2010124089A3 (en) Nepicastat for treating dependence
ECSP11010824A (es) Tratamiento para diabetes en pacientes inapropiados para terapia con metformina.
WO2010036395A3 (en) Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
MX2010006823A (es) Metodos para el tratamiento de la gota.
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
TN2011000239A1 (en) Hsp90 inhibitor combinations
PH12014500261A1 (en) Synthetic triterpenoids and methods of use in the treatment of disease
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
DK2139483T3 (da) Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer
WO2011127058A8 (en) Biomarkers for mdm2 inhibitors for use in treating disease
GT201100118A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores hif
EA201070609A1 (ru) Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
ZA201000173B (en) Method for treating an at least partially metallised textile, treated textile and the use thereof
BR112013004850A2 (pt) tratamento de infarto do miocárdio usando antagonistas tgf-beta
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
DE602005015841D1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
BRPI0819195A2 (pt) métodos para tratar escleroderma em um paciente em necessidade de tal tratamento e para aliviar um ou mais dos sintomas associados com escleroderma em um paciente em necessidade de tal tratamento.
MX373643B (es) Uso de acido sialico, precursor de acido sialico o una combinacion de los anteriores para preparar medicamentos utiles en una condicion diabetica o sindrome nefrotico.
WO2010040803A3 (en) Kv1.3 channel blocking substances for the treatment of diseases associated with intimal hyperplasia
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
EA201000433A1 (ru) Лечение вазомоторных симптомов
DK1861080T3 (da) Idebenon til behandling af muskeldystrofier
NO20092078L (no) Fremgangsmate for behandling av alkoholmisbruk, adiksjon og avhengighet
DK2155179T3 (da) Axomadol til smertebehandling arthrose